Showing 721-730 of 806 results for "".
- Cutera Unveils Free Digital Resources to Help Practices Thrive Through COVID-19 and Beyondhttps://practicaldermatology.com/news/cutera-unveils-new-free-digital-resources-to-help-practices-thrive-through-covid-19-and-beyond/2460366/CUTERA, INC. is launching the Cutera University e-learning series to support medical professionals through the COVID-19 crisis and beyond. The Cutera University e-learning series offers compli
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- Bonti's Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgeryhttps://practicaldermatology.com/news/bontis-novel-neurotoxin-shines-in-early-study-of-scar-reduction-after-mohs-surgery/2457662/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Nerium International Announces Creation of Scientific Advisory Boardhttps://practicaldermatology.com/news/20141027-nerium_international_announces_creation_of_scientific_advisory_board/2459078/Nerium International established a Scientific Advisory Board, comprised of the following scientists and dermatologists: Dr. Adam Friedman, Dr. Neal Bhatia, Dr. Mira Stotland, Marie Bertrand, Dr. Debra J. Wattenberg, and Dr. Karthik Krishnamurthy. The mission of the
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- IgE Identified as Key Mediator in Psoriasis and Atherosclerosis Comorbidityhttps://practicaldermatology.com/news/ige-identified-as-key-mediator-in-psoriasis-and-atherosclerosis-comorbidity/2471009/A new review points to immunoglobulin E (IgE) as a potential central player in the overlapping mechanisms of psoriasis and atherosclerosis. Researchers writing in Biomedicine and Pharmacotherapy proposed IgE-mediated mast cell (MC) activation as a significant contributor to the progressio